KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Non Operating Income: 2015-2025

Historic Non Operating Income for Arbutus Biopharma (ABUS) over the last 11 years, with Sep 2025 value amounting to $917,000.

  • Arbutus Biopharma's Non Operating Income fell 46.78% to $917,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 29.64%. This contributed to the annual value of $6.4 million for FY2024, which is 21.79% up from last year.
  • As of Q3 2025, Arbutus Biopharma's Non Operating Income stood at $917,000, which was down 11.40% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Non Operating Income registered a high of $1.8 million during Q2 2024, and its lowest value of -$750,000 during Q3 2021.
  • For the 3-year period, Arbutus Biopharma's Non Operating Income averaged around $1.3 million, with its median value being $1.4 million (2024).
  • As far as peak fluctuations go, Arbutus Biopharma's Non Operating Income soared by 1,655.42% in 2023, and later plummeted by 46.78% in 2025.
  • Quarterly analysis of 5 years shows Arbutus Biopharma's Non Operating Income stood at -$525,000 in 2021, then skyrocketed by 220.00% to $630,000 in 2022, then surged by 127.78% to $1.4 million in 2023, then fell by 2.37% to $1.4 million in 2024, then tumbled by 46.78% to $917,000 in 2025.
  • Its Non Operating Income stands at $917,000 for Q3 2025, versus $1.0 million for Q2 2025 and $1.2 million for Q1 2025.